Scarica l'app Stockscreener
8.60
1.04%
-0.09
Dopo l'orario di chiusura:
8.60
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka
TransCode Therapeutics Delays 2025 Annual Filing - TipRanks
Bank Watch: Is TransCode Therapeutics Inc attractive for institutional investorsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is TransCode Therapeutics Inc attractive for institutional investorsWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan
Growth Value: Is TransCode Therapeutics Inc showing insider buying2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Gap Down: Is TransCode Therapeutics Inc subject to activist investor interestAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Volume: What are analysts price targets for TransCode Therapeutics IncDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Mood: Does TransCode Therapeutics Inc have pricing power2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Bond Watch: Whats the outlook for TransCode Therapeutics Incs sector2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Understanding the Setup: (RNAZ) and Scalable Risk - Stock Traders Daily
Portfolio Update: Will TransCode Therapeutics Inc benefit from sector rotation2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
Is TransCode Therapeutics Inc undervalued by DCF analysis2026 Spike Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Breakout Zone: Should I hold or sell TransCode Therapeutics Inc now2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Aug Chart Watch: Is TransCode Therapeutics Inc showing insider buyingWeekly Profit Summary & Momentum Based Trading Ideas - baoquankhu1.vn
The Technical Signals Behind (RNAZ) That Institutions Follow - Stock Traders Daily
RNAZ Should I Buy - Intellectia AI
How interest rate cuts could boost TransCode Therapeutics Inc. stockWeekly Profit Analysis & Safe Swing Trade Setup Alerts - Naître et grandir
Bank Watch: Is TransCode Therapeutics Inc a good ESG investmentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Aug Macro: Can TransCode Therapeutics Inc disrupt its industryJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Weekly: Is TransCode Therapeutics Inc a speculative investmentTrend Reversal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Revista ADVFN
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - The Globe and Mail
TransCode Therapeutics (NASDAQ: RNAZ) adds Unleash oncolytic platform in all-stock licensing deal - Stock Titan
TransCode licenses bladder cancer therapy platform from Unleash - Investing.com
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics Incenters exclusive license agreement with Unleash - marketscreener.com
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
TransCode licenses bladder cancer therapy platform from Unleash By Investing.com - Investing.com India
RNAZTransCode Therapeutics Announces Strategic Expansion of its Product Portfolio - mx.advfn.com
RNAZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules - mx.advfn.com
TransCode Therapeutics (NASDAQ:RNAZ) Shares Up 0.8% – Still a Buy? - Defense World
Fed Watch: Is TransCode Therapeutics Inc showing insider buyingPortfolio Risk Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Buyout Rumor: Why is TransCode Therapeutics Inc stock going downEarnings Overview Report & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Gainers: Is TransCode Therapeutics Inc subject to activist investor interestMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
TransCode Unveils Tumor-Selective RIG-I Agonist Imaging Strategy - TipRanks
TransCode Therapeutics publishes preclinical RIG-I agonist study showing tumor-selective activation, supports TTX platform - TradingView
TransCode Therapeutics (RNAZ) highlights RIG-I cancer immunotherapy study in 8-K - Stock Titan
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - PR Newswire
New cancer approach uses tumor RNA to trigger immune attack in cells - Stock Titan
Will TransCode Therapeutics Inc. stock benefit from green energy trendsQuarterly Trade Summary & Free Reliable Trade Execution Plans - mfd.ru
Technical Reactions to RNAZ Trends in Macro Strategies - Stock Traders Daily
Technical Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs - GlobeNewswire Inc.
Sell Signal: Can TransCode Therapeutics Inc benefit from deglobalizationCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock a top momentum playJuly 2025 Decliners & Low Risk Growth Stock Ideas - mfd.ru
Can TransCode Therapeutics Inc. sustain its profitability2025 Major Catalysts & Intraday High Probability Setup Alerts - mfd.ru
Why is TransCode Therapeutics Inc. stock going downMarket Sentiment Review & Weekly High Conviction Ideas - mfd.ru
Movement Recap: Is TransCode Therapeutics Inc showing insider buyingWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
Aug Selloffs: Will TransCode Therapeutics Inc benefit from geopolitical trendsProfit Target & Smart Investment Allocation Insights - baoquankhu1.vn
Can TransCode Therapeutics Inc. disrupt its industryPortfolio Update Report & AI Powered Buy and Sell Recommendations - mfd.ru
What’s the beta of TransCode Therapeutics Inc. stockJuly 2025 Sentiment & Daily Stock Trend Watchlist - mfd.ru
ETF Watch: How correlated is FBYDW to the S P500July 2025 Outlook & Real-Time Volume Spike Alerts - baoquankhu1.vn
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial - TechStock²
Therapeutics, Inc. (RNAZ) Stock: Jumps as Company Expands RNA Cancer Program into Colorectal Indication - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Unveils Promising Glioblastoma Data with TTX-MC138 - timothysykes.com
TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade
TransCode Therapeutics: Promising Data Boosts Future Outlook - timothysykes.com
TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial - TipRanks
TransCode Therapeutics Announces IND Amendment for Phase 2a Trial - TradingView
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial With TTX-MC138 - 富途牛牛
Gainers Report: Does TransCode Therapeutics Inc have pricing powerRisk Management & Long-Term Growth Portfolio Plans - baoquankhu1.vn
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):